Drug Profile


Alternative Names: DB 102; Enzastaurin hydrochloride; Kinenza®; LY-317615

Latest Information Update: 01 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer Denovo Biopharma; Eli Lilly
  • Class Antineoplastics; Indoles; Piperidines; Pyridines; Pyrrolidinones; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Protein kinase C beta inhibitors; Protein-serine-threonine kinase inhibitors; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Diffuse large B cell lymphoma
  • Discontinued Brain cancer; Breast cancer; Cancer; Colorectal cancer; Follicular lymphoma; Glioblastoma; Lung cancer; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Renal cancer; Solid tumours; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 24 Oct 2017 US FDA approves IND application for enzastaurin in Diffuse Large B Cell Lymphoma
  • 17 Feb 2017 Clinical trials in Diffuse large B cell lymphoma (First-line therapy) in USA and China (PO)
  • 16 Feb 2017 Denovo Biopharma plans the randomised, double-blind, placebo-controlled, global phase III ENGINE trial for Diffuse large B cell lymphoma (DGM1 biomarker positive, First-line therapy, Combination therapy) in USA and China (PO) (NCT03263026)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top